A process for preparing a nitrated compound, including the step of reacting a compound (A) including at least one substituted or unsubstituted aromatic or heteroaromatic ring, wherein the heteroaromatic ring includes at least one heteroatom selected from the group consisting of oxygen, sulfur, phosphor, selenium and nitrogen, with a compound of formula (I)

##STR00001##

wherein Y is selected from the group consisting of hydrogen and nitro.

An isoxazoline-substituted benzamide compound, and the salt thereof. For example, a compound having the following formula:

##STR00001##

and pesticides characterized by containing the compound as an active ingredient.

An isoxazoline-substituted benzamide compound, and the salt thereof. For example, a compound having the following formula:

##STR00001##

and pesticides characterized by containing the compound as an active ingredient.

A Covid-19 susceptibility testing device including a receiving chamber configured to receive a human bodily fluid and a reaction medium configured to indicate Covid-19 susceptibility when concentration of an analyte exceeds a predetermined threshold in the human bodily fluid.

A Covid-19 susceptibility testing device including a receiving chamber configured to receive a human bodily fluid and a reaction medium configured to indicate Covid-19 susceptibility when concentration of an analyte exceeds a predetermined threshold in the human bodily fluid.

The present invention provides compositions, methods, and kits comprising one or more compounds of Formula I, such as XY018, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, gastric cancer, lymphoma, and glioma.

The present invention provides compositions, methods, and kits comprising one or more compounds of Formula I, such as XY018, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, gastric cancer, lymphoma, and glioma.

Described herein are labeling agents, specifically [.sup.11C]fluoroform, [.sup.11C]difluoromethane, [.sup.11C]fluoromethyl iodide, [.sup.11C]fluoromethyl bromide, [.sup.11C]fluoromethyl chloride, [.sup.11C]fluoromethyl trifluoromethansulfonate, [.sup.11C]difluoromethyl iodide, [.sup.11C]difluoromethyl bromide, [.sup.11C]difluoromethyl chloride, [.sup.11C]difluoromethyl trifluoromethansulfonate, [.sup.11C]trifluoromethyl iodide, [.sup.11C]trifluoromethyl bromide, [.sup.11C]trifluoromethyl chloride, [.sup.11C]trifluoromethyl trifluoromethansulfonate, [.sup.18]fluoroform, [.sup.18F]difluoromethane, [.sup.18F]difluoromethyl bromide or [.sup.18F]trifluoromethyl bromide. Also included are methods of labeling precursors to provide labeled fluoroalkanes and imaging methods.

Described herein are labeling agents, specifically [.sup.11C]fluoroform, [.sup.11C]difluoromethane, [.sup.11C]fluoromethyl iodide, [.sup.11C]fluoromethyl bromide, [.sup.11C]fluoromethyl chloride, [.sup.11C]fluoromethyl trifluoromethansulfonate, [.sup.11C]difluoromethyl iodide, [.sup.11C]difluoromethyl bromide, [.sup.11C]difluoromethyl chloride, [.sup.11C]difluoromethyl trifluoromethansulfonate, [.sup.11C]trifluoromethyl iodide, [.sup.11C]trifluoromethyl bromide, [.sup.11C]trifluoromethyl chloride, [.sup.11C]trifluoromethyl trifluoromethansulfonate, [.sup.18]fluoroform, [.sup.18F]difluoromethane, [.sup.18F]difluoromethyl bromide or [.sup.18F]trifluoromethyl bromide. Also included are methods of labeling precursors to provide labeled fluoroalkanes and imaging methods.

The present invention concerns a method of synthesizing a iodo- or astatoarene comprising the reaction of a diaryliodonium compound with a iodide or astatide salt, respectively. The invention also relates to said iodo- or astatoarene and diaryliodonium compound as such. The invention also concerns a method of synthesizing a iodo- or astatolabelled biomolecule and/or vector using said iodo- or astatoarene.